Bulletins announcing new coverage options for state Medicaid programs were released by CMS today outlining new support for babies, mothers, and pregnant women affected by substance and opioid use disorders.
Bulletins announcing new coverage options for state Medicaid programs were released by CMS today outlining new support for babies, mothers, and pregnant women affected by substance and opioid use disorders.
In a recent study, researchers sought to better understand medication disposal behaviors in order to help inform the design of future innovative drug take-back programs.
In a recent study, researchers sought to better understand medication disposal behaviors in order to help inform the design of future innovative drug take-back programs.
According to recent research published online in JAMA Network Open, reduced costs and health care utilization was observed when targeted drug delivery was added to conventional medical management for patients with cancer-related pain.
According to recent research published online in JAMA Network Open, reduced costs and health care utilization was observed when targeted drug delivery was added to conventional medical management for patients with cancer-related pain.
According to a recent analysis, a new program that provides support and resources to patients with chronic pain shows promise in reducing inappropriate opioid use.
According to a recent analysis, a new program that provides support and resources to patients with chronic pain shows promise in reducing inappropriate opioid use.
“These findings are important,” researchers wrote, “given the growing literature indicating that nonpharmacologic treatments for chronic, noncancer pain can reduce opioid exposure and overuse and improve patients’ quality of care and pain...
“These findings are important,” researchers wrote, “given the growing literature indicating that nonpharmacologic treatments for chronic, noncancer pain can reduce opioid exposure and overuse and improve patients’ quality of care and pain...
A multidisciplinary expert panel identified challenges to implementing the US Centers for Disease Control and Prevention’s opioid prescribing guidelines, most of which were in regard to the millions of Americans who take opioids for chronic...
A multidisciplinary expert panel identified challenges to implementing the US Centers for Disease Control and Prevention’s opioid prescribing guidelines, most of which were in regard to the millions of Americans who take opioids for chronic...
“Knowledge of risk factors and predictors of opioid-related adverse drug events can help develop targeted interventions to minimize the development of these potentially dangerous and costly events,” researchers wrote.
“Knowledge of risk factors and predictors of opioid-related adverse drug events can help develop targeted interventions to minimize the development of these potentially dangerous and costly events,” researchers wrote.
Inappropriate imaging accounted for more than 20% of annual imaging costs for patients with uncomplicated low back pain, nontraumatic knee pain, or nontraumatic shoulder pain, according to a study published online in the International Journal...
Inappropriate imaging accounted for more than 20% of annual imaging costs for patients with uncomplicated low back pain, nontraumatic knee pain, or nontraumatic shoulder pain, according to a study published online in the International Journal...
Researchers found that insurance plans vary widely in what they will cover and private and public insurers are missing important opportunities to promote alternatives to opioids.
Researchers found that insurance plans vary widely in what they will cover and private and public insurers are missing important opportunities to promote alternatives to opioids.
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
